Drugs, ISSN 0012-6667, 06/2000, Volume 59, Issue 6, pp. 1261 - 1277
Neuroblastoma represents one of the most challenging malignancies for treatment decisions because of its unusual biological behaviour. The features include...
Melphalan, pharmacokinetics | Topoisomerase inhibitors, therapeutic use | Cytarabine, pharmacokinetics | Teniposide, therapeutic use | Fluorouracil, pharmacokinetics | Research and development | Thioguanine, pharmacokinetics | Hydroxycarbamide, pharmacokinetics | Etoposide, pharmacokinetics | Vincristine, pharmacokinetics | Thiotepa, pharmacokinetics | Cisplatin, pharmacokinetics | Doxorubicin, pharmacokinetics | Zilascorb, pharmacokinetics | Procarbazine, pharmacokinetics | Cyclophosphamide, pharmacokinetics | Antineoplastics, therapeutic use | Bleomycin, pharmacokinetics | Busulfan, pharmacokinetics | Dacarbazine, therapeutic use | Ifosfamide, pharmacokinetics | Vinblastine, therapeutic use | Dactinomycin, pharmacokinetics | Lomustine, pharmacokinetics | Mercaptopurine, pharmacokinetics | Carboplatin, pharmacokinetics | Mitoxantrone, pharmacokinetics | Neuroblastoma, treatment | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | NEURO-BLASTOMA | BONE-MARROW TRANSPLANTATION | MESSENGER-RNA | CHROMOSOME 1P | PEDIATRIC-ONCOLOGY-GROUP | METASTATIC NEUROBLASTOMA | CHILDHOOD NEUROBLASTOMA | CLINICAL RELEVANCE | GENE AMPLIFICATION | PHARMACOLOGY & PHARMACY | TOXICOLOGY | MULTIDRUG-RESISTANCE | Prognosis | Humans | Neuroblastoma - drug therapy | Hematopoietic Stem Cell Transplantation | Drug Resistance, Neoplasm | Transplantation, Autologous | Neuroblastoma - mortality
Melphalan, pharmacokinetics | Topoisomerase inhibitors, therapeutic use | Cytarabine, pharmacokinetics | Teniposide, therapeutic use | Fluorouracil, pharmacokinetics | Research and development | Thioguanine, pharmacokinetics | Hydroxycarbamide, pharmacokinetics | Etoposide, pharmacokinetics | Vincristine, pharmacokinetics | Thiotepa, pharmacokinetics | Cisplatin, pharmacokinetics | Doxorubicin, pharmacokinetics | Zilascorb, pharmacokinetics | Procarbazine, pharmacokinetics | Cyclophosphamide, pharmacokinetics | Antineoplastics, therapeutic use | Bleomycin, pharmacokinetics | Busulfan, pharmacokinetics | Dacarbazine, therapeutic use | Ifosfamide, pharmacokinetics | Vinblastine, therapeutic use | Dactinomycin, pharmacokinetics | Lomustine, pharmacokinetics | Mercaptopurine, pharmacokinetics | Carboplatin, pharmacokinetics | Mitoxantrone, pharmacokinetics | Neuroblastoma, treatment | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | NEURO-BLASTOMA | BONE-MARROW TRANSPLANTATION | MESSENGER-RNA | CHROMOSOME 1P | PEDIATRIC-ONCOLOGY-GROUP | METASTATIC NEUROBLASTOMA | CHILDHOOD NEUROBLASTOMA | CLINICAL RELEVANCE | GENE AMPLIFICATION | PHARMACOLOGY & PHARMACY | TOXICOLOGY | MULTIDRUG-RESISTANCE | Prognosis | Humans | Neuroblastoma - drug therapy | Hematopoietic Stem Cell Transplantation | Drug Resistance, Neoplasm | Transplantation, Autologous | Neuroblastoma - mortality
Journal Article
Anti-Cancer Agents in Medicinal Chemistry, ISSN 1871-5206, 2013, Volume 13, Issue 8, pp. 1197 - 1203
Several nutritional assessment tools have been used in oncology settings to monitor nutritional status and its associated prognostic significance. Body...
Nutritional assessment | Cancer prognosis | Chemotherapy treatment | Pharmacokinetics | Body composition | Nutritional status | Cancer | nutritional status | CHEMISTRY, MEDICINAL | PROTEIN | DETERMINANT | LEAN TISSUE | cancer prognosis | CHEMOTHERAPY TOXICITY | BREAST-CANCER | chemotherapy treatment | SURFACE AREA | COMPOSITION PARAMETERS | ONCOLOGY | SARCOPENIC OBESITY | MASS | pharmacokinetics | cancer | nutritional assessment | INDEX | Body Composition | Body Mass Index | Neoplasms - metabolism | Niacinamide - analogs & derivatives | Fluorouracil - analogs & derivatives | Capecitabine | Deoxycytidine - administration & dosage | Humans | Antineoplastic Agents - administration & dosage | Neoplasms - drug therapy | Niacinamide - administration & dosage | Deoxycytidine - pharmacokinetics | Fluorouracil - administration & dosage | Phenylurea Compounds - administration & dosage | Niacinamide - pharmacokinetics | Antineoplastic Agents - pharmacokinetics | Nutritional Status | Phenylurea Compounds - pharmacokinetics | Neoplasms - physiopathology | Fluorouracil - pharmacokinetics | Nutritional Support | Deoxycytidine - analogs & derivatives
Nutritional assessment | Cancer prognosis | Chemotherapy treatment | Pharmacokinetics | Body composition | Nutritional status | Cancer | nutritional status | CHEMISTRY, MEDICINAL | PROTEIN | DETERMINANT | LEAN TISSUE | cancer prognosis | CHEMOTHERAPY TOXICITY | BREAST-CANCER | chemotherapy treatment | SURFACE AREA | COMPOSITION PARAMETERS | ONCOLOGY | SARCOPENIC OBESITY | MASS | pharmacokinetics | cancer | nutritional assessment | INDEX | Body Composition | Body Mass Index | Neoplasms - metabolism | Niacinamide - analogs & derivatives | Fluorouracil - analogs & derivatives | Capecitabine | Deoxycytidine - administration & dosage | Humans | Antineoplastic Agents - administration & dosage | Neoplasms - drug therapy | Niacinamide - administration & dosage | Deoxycytidine - pharmacokinetics | Fluorouracil - administration & dosage | Phenylurea Compounds - administration & dosage | Niacinamide - pharmacokinetics | Antineoplastic Agents - pharmacokinetics | Nutritional Status | Phenylurea Compounds - pharmacokinetics | Neoplasms - physiopathology | Fluorouracil - pharmacokinetics | Nutritional Support | Deoxycytidine - analogs & derivatives
Journal Article
Molecules, ISSN 1420-3049, 09/2017, Volume 22, Issue 9, p. 1488
S-1 (TS-1 (R)) is an oral fluoropyrimidine anticancer agent containing tegafur, oteracil, and gimeracil. Sipjeondaebo-tang (SDT) is a traditional oriental...
Herbal medicine | Sipjeondaebo-tang | Drug-drug interaction | Pharmacokinetics | Gimeracil | 5-FU | CYTOCHROME-P450 2A6 | gimeracil | BIOCHEMISTRY & MOLECULAR BIOLOGY | TEGAFUR | PHASE-II | BIOACTIVATION | PHARMACODYNAMICS | CHEMISTRY, MULTIDISCIPLINARY | 5-FLUOROURACIL | GASTRIC-CANCER | GROWTH | pharmacokinetics | JUZEN-TAIHO-TO | herbal medicine | drug-drug interaction | Fluorouracil - metabolism | Antimetabolites, Antineoplastic - pharmacokinetics | Administration, Oral | Pyridines - chemistry | Humans | Drugs, Chinese Herbal - pharmacology | Pyridines - pharmacokinetics | Male | Oxonic Acid - chemistry | Antimetabolites, Antineoplastic - chemistry | Rats, Sprague-Dawley | Tegafur - pharmacokinetics | Animals | Drugs, Chinese Herbal - chemistry | Models, Biological | Herb-Drug Interactions | Tegafur - chemistry | Oxonic Acid - pharmacokinetics | Drugs, Chinese Herbal - administration & dosage | Drug Combinations | Tegafur | Oral administration | Rats | Mass spectroscopy | Liquid chromatography | Pharmacology | Metabolism | Dosage | Anticancer properties | Chemotherapy | Absorption | Rodents | Modelling | Plasma levels | Pretreatment | Mass spectrometry | Cancer | Plasmas (physics)
Herbal medicine | Sipjeondaebo-tang | Drug-drug interaction | Pharmacokinetics | Gimeracil | 5-FU | CYTOCHROME-P450 2A6 | gimeracil | BIOCHEMISTRY & MOLECULAR BIOLOGY | TEGAFUR | PHASE-II | BIOACTIVATION | PHARMACODYNAMICS | CHEMISTRY, MULTIDISCIPLINARY | 5-FLUOROURACIL | GASTRIC-CANCER | GROWTH | pharmacokinetics | JUZEN-TAIHO-TO | herbal medicine | drug-drug interaction | Fluorouracil - metabolism | Antimetabolites, Antineoplastic - pharmacokinetics | Administration, Oral | Pyridines - chemistry | Humans | Drugs, Chinese Herbal - pharmacology | Pyridines - pharmacokinetics | Male | Oxonic Acid - chemistry | Antimetabolites, Antineoplastic - chemistry | Rats, Sprague-Dawley | Tegafur - pharmacokinetics | Animals | Drugs, Chinese Herbal - chemistry | Models, Biological | Herb-Drug Interactions | Tegafur - chemistry | Oxonic Acid - pharmacokinetics | Drugs, Chinese Herbal - administration & dosage | Drug Combinations | Tegafur | Oral administration | Rats | Mass spectroscopy | Liquid chromatography | Pharmacology | Metabolism | Dosage | Anticancer properties | Chemotherapy | Absorption | Rodents | Modelling | Plasma levels | Pretreatment | Mass spectrometry | Cancer | Plasmas (physics)
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 4/2014, Volume 73, Issue 4, pp. 737 - 747
The aim of this study was to characterize trastuzumab population pharmacokinetics (PKs) in patients with human epidermal growth factor receptor 2-positive...
Population pharmacokinetics | Gastroesophageal junction cancer | Medicine & Public Health | Exposure–response | Oncology | Cancer Research | Pharmacology/Toxicology | Gastric cancer | Trastuzumab | Exposure-response | SURVIVAL | EGF | RECEPTOR | HER-2 | AMPLIFICATION | GENE | ONCOLOGY | PHARMACOLOGY & PHARMACY | rastuzumab | Receptor, ErbB-2 - genetics | Capecitabine | Esophageal Neoplasms - blood | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Receptor, ErbB-2 - metabolism | Stomach Neoplasms - metabolism | Male | Stomach Neoplasms - pathology | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Young Adult | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Antibodies, Monoclonal, Humanized - blood | Esophageal Neoplasms - metabolism | Aged, 80 and over | Adult | Female | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Esophagogastric Junction - metabolism | Esophagogastric Junction - pathology | Stomach Neoplasms - drug therapy | Stomach Neoplasms - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Esophageal Neoplasms - drug therapy | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Epidermal growth factor | Analysis | Antineoplastic agents | Cancer
Population pharmacokinetics | Gastroesophageal junction cancer | Medicine & Public Health | Exposure–response | Oncology | Cancer Research | Pharmacology/Toxicology | Gastric cancer | Trastuzumab | Exposure-response | SURVIVAL | EGF | RECEPTOR | HER-2 | AMPLIFICATION | GENE | ONCOLOGY | PHARMACOLOGY & PHARMACY | rastuzumab | Receptor, ErbB-2 - genetics | Capecitabine | Esophageal Neoplasms - blood | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Receptor, ErbB-2 - metabolism | Stomach Neoplasms - metabolism | Male | Stomach Neoplasms - pathology | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Young Adult | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Antibodies, Monoclonal, Humanized - blood | Esophageal Neoplasms - metabolism | Aged, 80 and over | Adult | Female | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Esophagogastric Junction - metabolism | Esophagogastric Junction - pathology | Stomach Neoplasms - drug therapy | Stomach Neoplasms - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Esophageal Neoplasms - drug therapy | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Epidermal growth factor | Analysis | Antineoplastic agents | Cancer
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 10/2008, Volume 62, Issue 5, pp. 779 - 786
To characterize the population pharmacokinetics of bevacizumab and the influence of demographic factors, disease severity, and concomitantly used chemotherapy...
Population pharmacokinetics | Biomedicine | Oncology | Cancer Research | Covariate effect | Monoclonal antibody | Pharmacology/Toxicology | Dosing schedule | Bevacizumab | LEUCOVORIN | dosing schedule | SAFETY | PHASE-II | ANTIBODY | FLUOROURACIL | METASTATIC COLORECTAL-CANCER | population pharmacokinetics | BREAST-CANCER | TRIAL | ONCOLOGY | bevacizumab | PHARMACOLOGY & PHARMACY | monoclonal antibody | covariate effect | ENDOTHELIAL GROWTH-FACTOR | Neoplasms - metabolism | Enzyme-Linked Immunosorbent Assay | Humans | Antibodies, Monoclonal - pharmacokinetics | Antibodies, Monoclonal - therapeutic use | Male | Angiogenesis Inhibitors - pharmacokinetics | Clinical Trials as Topic | Neoplasms - drug therapy | Antibodies, Monoclonal, Humanized | Angiogenesis Inhibitors - administration & dosage | Clinical Trials, Phase III as Topic | Algorithms | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Computer Simulation | Angiogenesis Inhibitors - therapeutic use | Female | Population | Neoplasms - physiopathology | Clinical Trials, Phase II as Topic | Care and treatment | Chemotherapy | Phosphatases | Immunoglobulin G | Albumin | Monoclonal antibodies | Angiogenesis inhibitors | Tumors | Cancer
Population pharmacokinetics | Biomedicine | Oncology | Cancer Research | Covariate effect | Monoclonal antibody | Pharmacology/Toxicology | Dosing schedule | Bevacizumab | LEUCOVORIN | dosing schedule | SAFETY | PHASE-II | ANTIBODY | FLUOROURACIL | METASTATIC COLORECTAL-CANCER | population pharmacokinetics | BREAST-CANCER | TRIAL | ONCOLOGY | bevacizumab | PHARMACOLOGY & PHARMACY | monoclonal antibody | covariate effect | ENDOTHELIAL GROWTH-FACTOR | Neoplasms - metabolism | Enzyme-Linked Immunosorbent Assay | Humans | Antibodies, Monoclonal - pharmacokinetics | Antibodies, Monoclonal - therapeutic use | Male | Angiogenesis Inhibitors - pharmacokinetics | Clinical Trials as Topic | Neoplasms - drug therapy | Antibodies, Monoclonal, Humanized | Angiogenesis Inhibitors - administration & dosage | Clinical Trials, Phase III as Topic | Algorithms | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Computer Simulation | Angiogenesis Inhibitors - therapeutic use | Female | Population | Neoplasms - physiopathology | Clinical Trials, Phase II as Topic | Care and treatment | Chemotherapy | Phosphatases | Immunoglobulin G | Albumin | Monoclonal antibodies | Angiogenesis inhibitors | Tumors | Cancer
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 12/2002, Volume 94, Issue 24, pp. 1883 - 1888
The prescribed dose of anticancer agents is most commonly calculated using body surface area as the only independent variable, and it has been shown that this...
TOPOISOMERASE-I INHIBITOR | INTRAVENOUS CISPLATIN | DOSE-ESCALATION | ADVANCED SOLID TUMORS | ONCOLOGY | ORAL TOPOTECAN | MATRIX-METALLOPROTEINASE INHIBITOR | SCHEDULE | CLINICAL PHARMACOKINETICS | PHASE-I | CREMOPHOR EL | Cytosine - analogs & derivatives | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Drugs, Investigational - pharmacokinetics | Cytosine - administration & dosage | Male | Paclitaxel - pharmacokinetics | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Fluorouracil - administration & dosage | Uracil - administration & dosage | Dacarbazine - analogs & derivatives | Adult | Dacarbazine - pharmacokinetics | Dioxolanes - pharmacokinetics | Female | Antineoplastic Agents - pharmacokinetics | Retrospective Studies | Body Surface Area | Paclitaxel - administration & dosage | Dacarbazine - administration & dosage | Cytosine - pharmacokinetics | Drug Administration Schedule | Docosahexaenoic Acids - administration & dosage | Docosahexaenoic Acids - pharmacokinetics | Drugs, Investigational - administration & dosage | Dioxolanes - administration & dosage | Infusions, Intravenous | Temozolomide | Fluorouracil - pharmacokinetics | Uracil - pharmacokinetics | Clinical Trials, Phase I as Topic | Uracil - analogs & derivatives | Antimitotic agents | Drug metabolism | Dosage and administration | Testolactone | Antineoplastic agents | Analysis
TOPOISOMERASE-I INHIBITOR | INTRAVENOUS CISPLATIN | DOSE-ESCALATION | ADVANCED SOLID TUMORS | ONCOLOGY | ORAL TOPOTECAN | MATRIX-METALLOPROTEINASE INHIBITOR | SCHEDULE | CLINICAL PHARMACOKINETICS | PHASE-I | CREMOPHOR EL | Cytosine - analogs & derivatives | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Drugs, Investigational - pharmacokinetics | Cytosine - administration & dosage | Male | Paclitaxel - pharmacokinetics | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Fluorouracil - administration & dosage | Uracil - administration & dosage | Dacarbazine - analogs & derivatives | Adult | Dacarbazine - pharmacokinetics | Dioxolanes - pharmacokinetics | Female | Antineoplastic Agents - pharmacokinetics | Retrospective Studies | Body Surface Area | Paclitaxel - administration & dosage | Dacarbazine - administration & dosage | Cytosine - pharmacokinetics | Drug Administration Schedule | Docosahexaenoic Acids - administration & dosage | Docosahexaenoic Acids - pharmacokinetics | Drugs, Investigational - administration & dosage | Dioxolanes - administration & dosage | Infusions, Intravenous | Temozolomide | Fluorouracil - pharmacokinetics | Uracil - pharmacokinetics | Clinical Trials, Phase I as Topic | Uracil - analogs & derivatives | Antimitotic agents | Drug metabolism | Dosage and administration | Testolactone | Antineoplastic agents | Analysis
Journal Article
Lab on a Chip, ISSN 1473-0197, 2010, Volume 10, Issue 4, pp. 446 - 455
Drug discovery is often impeded by the poor predictability of in vitro assays for drug toxicity. One primary reason for this observation is the inability to...
MODIFIED ALGINATE | RAT | DIHYDROPYRIMIDINE DEHYDROGENASE | DRUG DISCOVERY | BIOCHEMICAL RESEARCH METHODS | TRANSDUCTION | NANOSCIENCE & NANOTECHNOLOGY | CELL-CULTURE ANALOG | BUBBLE TRAP | CHEMISTRY, MULTIDISCIPLINARY | 5-FLUOROURACIL | ASSAYS | NAPHTHALENE TOXICITY | Microfluidic Analytical Techniques - methods | Cell Survival - drug effects | Gravitation | HCT116 Cells | Humans | Computational Biology | Microfluidic Analytical Techniques - instrumentation | Fluorouracil - toxicity | Equipment Design | Animals | Pharmacological Phenomena | Models, Biological | Drug-Related Side Effects and Adverse Reactions | Fluorouracil - pharmacology | Fluorouracil - pharmacokinetics | Pharmacokinetics | Index Medicus
MODIFIED ALGINATE | RAT | DIHYDROPYRIMIDINE DEHYDROGENASE | DRUG DISCOVERY | BIOCHEMICAL RESEARCH METHODS | TRANSDUCTION | NANOSCIENCE & NANOTECHNOLOGY | CELL-CULTURE ANALOG | BUBBLE TRAP | CHEMISTRY, MULTIDISCIPLINARY | 5-FLUOROURACIL | ASSAYS | NAPHTHALENE TOXICITY | Microfluidic Analytical Techniques - methods | Cell Survival - drug effects | Gravitation | HCT116 Cells | Humans | Computational Biology | Microfluidic Analytical Techniques - instrumentation | Fluorouracil - toxicity | Equipment Design | Animals | Pharmacological Phenomena | Models, Biological | Drug-Related Side Effects and Adverse Reactions | Fluorouracil - pharmacology | Fluorouracil - pharmacokinetics | Pharmacokinetics | Index Medicus
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 05/2015, Volume 32, Issue 5, pp. 1585 - 1603
We optimize the encapsulation and investigate the pharmacokinetics of 5-Fluorouracil (5-FU) delivered by thermosensitive stealth(A (R)) liposomes (TSLs)...
thermosensitive stealth® liposomes | pharmacokinetics | copper-polyethylenimine complex | 5-Fluorouracil | focused ultrasound | STERICALLY STABILIZED LIPOSOMES | thermosensitive stealth (R) liposomes | LOADED LIPOSOMES | RELEASE | TEMPERATURE-SENSITIVE LIPOSOMES | ANTITUMOR-ACTIVITY | CHEMISTRY, MULTIDISCIPLINARY | IN-VITRO | MILD HYPERTHERMIA | MEDIATED DRUG-DELIVERY | TISSUE DISTRIBUTION | PHARMACOLOGY & PHARMACY | Antimetabolites, Antineoplastic - pharmacokinetics | Humans | Male | Polyethylene Glycols - chemistry | Antimetabolites, Antineoplastic - administration & dosage | Cholesterol - chemistry | HT29 Cells | Tissue Distribution | Liposomes - chemistry | Animals | Fluorouracil - administration & dosage | 1,2-Dipalmitoylphosphatidylcholine - analogs & derivatives | Polyethyleneimine - chemistry | Hyperthermia, Induced | Drug Liberation | Antimetabolites, Antineoplastic - pharmacology | 1,2-Dipalmitoylphosphatidylcholine - chemistry | Fluorouracil - pharmacology | Mice | Mice, Inbred BALB C | Fluorouracil - pharmacokinetics | Phosphatidylethanolamines - chemistry | Index Medicus
thermosensitive stealth® liposomes | pharmacokinetics | copper-polyethylenimine complex | 5-Fluorouracil | focused ultrasound | STERICALLY STABILIZED LIPOSOMES | thermosensitive stealth (R) liposomes | LOADED LIPOSOMES | RELEASE | TEMPERATURE-SENSITIVE LIPOSOMES | ANTITUMOR-ACTIVITY | CHEMISTRY, MULTIDISCIPLINARY | IN-VITRO | MILD HYPERTHERMIA | MEDIATED DRUG-DELIVERY | TISSUE DISTRIBUTION | PHARMACOLOGY & PHARMACY | Antimetabolites, Antineoplastic - pharmacokinetics | Humans | Male | Polyethylene Glycols - chemistry | Antimetabolites, Antineoplastic - administration & dosage | Cholesterol - chemistry | HT29 Cells | Tissue Distribution | Liposomes - chemistry | Animals | Fluorouracil - administration & dosage | 1,2-Dipalmitoylphosphatidylcholine - analogs & derivatives | Polyethyleneimine - chemistry | Hyperthermia, Induced | Drug Liberation | Antimetabolites, Antineoplastic - pharmacology | 1,2-Dipalmitoylphosphatidylcholine - chemistry | Fluorouracil - pharmacology | Mice | Mice, Inbred BALB C | Fluorouracil - pharmacokinetics | Phosphatidylethanolamines - chemistry | Index Medicus
Journal Article
Current Medicinal Chemistry, ISSN 0929-8673, 01/2017, Volume 24, Issue 2, pp. 193 - 214
Cancer is the uncontrolled growth of cells in the body and is considered as one of the major causes of death globally. There are several cytotoxic...
Cytotoxicity | Chemotherapy | Metal organic frameworks (MOFs) | Loading | Release | Cancer | CANCER-CELLS | CHEMISTRY, MEDICINAL | CURCUMIN | release | BIOCHEMISTRY & MOLECULAR BIOLOGY | DOXORUBICIN | ENCAPSULATION | SURFACE MODIFICATION | metal organic frameworks (MOFs) | loading | chemotherapy | ZEOLITIC IMIDAZOLATE FRAMEWORKS | NANOPARTICLES | THERAPY | PHARMACOLOGY & PHARMACY | cytotoxicity | TUMOR MICROENVIRONMENT | Humans | Succinates - pharmacokinetics | Antineoplastic Agents - administration & dosage | Busulfan - administration & dosage | Organoplatinum Compounds - pharmacology | Drug Carriers | Nanoparticles | Fluorouracil - administration & dosage | Organoplatinum Compounds - pharmacokinetics | Camptothecin - administration & dosage | Antineoplastic Agents - pharmacokinetics | Doxorubicin - administration & dosage | Camptothecin - pharmacokinetics | Busulfan - pharmacokinetics | Polymers - chemical synthesis | Doxorubicin - pharmacokinetics | Organometallic Compounds - chemical synthesis | Topotecan - pharmacokinetics | Cell Line, Tumor | Topotecan - administration & dosage | Organometallic Compounds - chemistry | Polymers - chemistry | Porosity | Fluorouracil - pharmacokinetics | Succinates - pharmacology
Cytotoxicity | Chemotherapy | Metal organic frameworks (MOFs) | Loading | Release | Cancer | CANCER-CELLS | CHEMISTRY, MEDICINAL | CURCUMIN | release | BIOCHEMISTRY & MOLECULAR BIOLOGY | DOXORUBICIN | ENCAPSULATION | SURFACE MODIFICATION | metal organic frameworks (MOFs) | loading | chemotherapy | ZEOLITIC IMIDAZOLATE FRAMEWORKS | NANOPARTICLES | THERAPY | PHARMACOLOGY & PHARMACY | cytotoxicity | TUMOR MICROENVIRONMENT | Humans | Succinates - pharmacokinetics | Antineoplastic Agents - administration & dosage | Busulfan - administration & dosage | Organoplatinum Compounds - pharmacology | Drug Carriers | Nanoparticles | Fluorouracil - administration & dosage | Organoplatinum Compounds - pharmacokinetics | Camptothecin - administration & dosage | Antineoplastic Agents - pharmacokinetics | Doxorubicin - administration & dosage | Camptothecin - pharmacokinetics | Busulfan - pharmacokinetics | Polymers - chemical synthesis | Doxorubicin - pharmacokinetics | Organometallic Compounds - chemical synthesis | Topotecan - pharmacokinetics | Cell Line, Tumor | Topotecan - administration & dosage | Organometallic Compounds - chemistry | Polymers - chemistry | Porosity | Fluorouracil - pharmacokinetics | Succinates - pharmacology
Journal Article
Annals of Oncology, ISSN 0923-7534, 06/2013, Volume 24, Issue 6, pp. 1560 - 1567
Background: Metastatic colorectal cancer (mCRC) is commonly treated with 5-fluorouracil, folinic acid, and oxaliplatin or irinotecan. The multitargeted kinase...
Regorafenib | Chemotherapy | Combination therapy | Tyrosine kinase inhibition | Colorectal cancer | 1ST-LINE TREATMENT | colorectal cancer | BEVACIZUMAB | PTK787/ZK 222584 | tyrosine kinase inhibition | OXALIPLATIN | regorafenib | FLUOROURACIL | chemotherapy | TRIAL | GROWTH-FACTOR RECEPTOR | PHARMACOKINETICS | ONCOLOGY | combination therapy | IRINOTECAN | INHIBITOR | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Pyridines - pharmacokinetics | Male | Young Adult | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Organoplatinum Compounds - pharmacokinetics | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Phenylurea Compounds - pharmacokinetics | Colorectal Neoplasms - metabolism | Camptothecin - analogs & derivatives | Camptothecin - pharmacokinetics | Pyridines - administration & dosage | Treatment Outcome | Leucovorin - pharmacokinetics | Phenylurea Compounds - administration & dosage | Adolescent | Aged | Colorectal Neoplasms - pathology | Fluorouracil - pharmacokinetics | Original
Regorafenib | Chemotherapy | Combination therapy | Tyrosine kinase inhibition | Colorectal cancer | 1ST-LINE TREATMENT | colorectal cancer | BEVACIZUMAB | PTK787/ZK 222584 | tyrosine kinase inhibition | OXALIPLATIN | regorafenib | FLUOROURACIL | chemotherapy | TRIAL | GROWTH-FACTOR RECEPTOR | PHARMACOKINETICS | ONCOLOGY | combination therapy | IRINOTECAN | INHIBITOR | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Pyridines - pharmacokinetics | Male | Young Adult | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Organoplatinum Compounds - pharmacokinetics | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Phenylurea Compounds - pharmacokinetics | Colorectal Neoplasms - metabolism | Camptothecin - analogs & derivatives | Camptothecin - pharmacokinetics | Pyridines - administration & dosage | Treatment Outcome | Leucovorin - pharmacokinetics | Phenylurea Compounds - administration & dosage | Adolescent | Aged | Colorectal Neoplasms - pathology | Fluorouracil - pharmacokinetics | Original
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 11/2009, Volume 15, Issue 21, pp. 6649 - 6657
Purpose: We showed in preclinical models that thymidylate synthase (TS) inhibition leads to redistribution of the nucleoside transporter, ENT1, to the cell...
breast cancer | Thymidylate synthase | Capecitabine | PET | FLT | DIPYRIDAMOLE | 5-FLUOROURACIL | GROWTH-INHIBITION | SOLID TUMORS | METABOLISM | ONCOLOGY | FOLATE RECEPTOR | THYMIDYLATE SYNTHASE INHIBITION | ELEVATION | PROLIFERATION | CHEMOTHERAPY | Fluorouracil - analogs & derivatives | Humans | Deoxycytidine - pharmacology | Positron-Emission Tomography | Breast Neoplasms - blood supply | Regional Blood Flow | Breast Neoplasms - metabolism | Dideoxynucleosides - pharmacokinetics | Antimetabolites, Antineoplastic - pharmacology | Fluorouracil - pharmacology | Breast Neoplasms - diagnostic imaging | Thymidylate Synthase - antagonists & inhibitors | Deoxycytidine - analogs & derivatives | Index Medicus
breast cancer | Thymidylate synthase | Capecitabine | PET | FLT | DIPYRIDAMOLE | 5-FLUOROURACIL | GROWTH-INHIBITION | SOLID TUMORS | METABOLISM | ONCOLOGY | FOLATE RECEPTOR | THYMIDYLATE SYNTHASE INHIBITION | ELEVATION | PROLIFERATION | CHEMOTHERAPY | Fluorouracil - analogs & derivatives | Humans | Deoxycytidine - pharmacology | Positron-Emission Tomography | Breast Neoplasms - blood supply | Regional Blood Flow | Breast Neoplasms - metabolism | Dideoxynucleosides - pharmacokinetics | Antimetabolites, Antineoplastic - pharmacology | Fluorouracil - pharmacology | Breast Neoplasms - diagnostic imaging | Thymidylate Synthase - antagonists & inhibitors | Deoxycytidine - analogs & derivatives | Index Medicus
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 06/2014, Volume 73, Issue 6, pp. 1285 - 93
PURPOSE: The aims of the present study were (1) to investigate the impact of great age on pharmacokinetics of capecitabine and its metabolites and (2) to...
Age Factors | Humans | Antineoplastic Combined Chemotherapy Protocols | Male | Breast Neoplasms | Life Sciences | Deoxycytidine | Aged, 80 and over | Antimetabolites, Antineoplastic | Colorectal Neoplasms | Female | Aged | Pharmaceutical sciences | Fluorouracil
Age Factors | Humans | Antineoplastic Combined Chemotherapy Protocols | Male | Breast Neoplasms | Life Sciences | Deoxycytidine | Aged, 80 and over | Antimetabolites, Antineoplastic | Colorectal Neoplasms | Female | Aged | Pharmaceutical sciences | Fluorouracil
Journal Article
Cancer Science, ISSN 1347-9032, 02/2011, Volume 102, Issue 2, pp. 478 - 483
S‐1 is an oral fluoropyrimidine anti‐neoplastic agent that is converted by CYP2A6 to 5‐fluorouracil (5FU). We prospectively studied the pharmacokinetics and...
ADJUVANT CHEMOTHERAPY | 5-FLUOROURACIL | IN-VITRO | CYP2A6 | SOLID TUMORS | ONCOLOGY | HUMAN LIVER-MICROSOMES | POLYMORPHISM | JAPANESE PATIENTS | PHASE-I | CANCER | Cytochrome P-450 CYP2A6 | European Continental Ancestry Group - genetics | Antimetabolites, Antineoplastic - pharmacokinetics | Area Under Curve | Humans | Middle Aged | Tegafur - adverse effects | Aryl Hydrocarbon Hydroxylases - genetics | Asian Continental Ancestry Group - genetics | Genotype | Male | Tegafur - pharmacokinetics | Oxonic Acid - adverse effects | Neoplasms - drug therapy | Phenotype | Antimetabolites, Antineoplastic - adverse effects | Adult | Female | Aged | Oxonic Acid - pharmacokinetics | Far East | Drug Combinations | Chemotherapy | Comparative analysis | Cytochrome P-450 | Fluorouracil | Cancer | Index Medicus
ADJUVANT CHEMOTHERAPY | 5-FLUOROURACIL | IN-VITRO | CYP2A6 | SOLID TUMORS | ONCOLOGY | HUMAN LIVER-MICROSOMES | POLYMORPHISM | JAPANESE PATIENTS | PHASE-I | CANCER | Cytochrome P-450 CYP2A6 | European Continental Ancestry Group - genetics | Antimetabolites, Antineoplastic - pharmacokinetics | Area Under Curve | Humans | Middle Aged | Tegafur - adverse effects | Aryl Hydrocarbon Hydroxylases - genetics | Asian Continental Ancestry Group - genetics | Genotype | Male | Tegafur - pharmacokinetics | Oxonic Acid - adverse effects | Neoplasms - drug therapy | Phenotype | Antimetabolites, Antineoplastic - adverse effects | Adult | Female | Aged | Oxonic Acid - pharmacokinetics | Far East | Drug Combinations | Chemotherapy | Comparative analysis | Cytochrome P-450 | Fluorouracil | Cancer | Index Medicus
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 1/2019, Volume 83, Issue 1, pp. 27 - 42
FOLFIRINOX regimen is commonly used in colorectal and more recently pancreatic cancer. However, FOLFIRINOX induces significant and dose-limiting toxic effects...
Irinotecan | Population pharmacokinetics | FOLFIRINOX | Nonlinear mixed effect modelling | Oxaliplatin | Medicine & Public Health | 5-Fluorouracil | Oncology | Cancer Research | Pharmacology/Toxicology | METABOLITES | LEUCOVORIN | OXALIPLATIN PLUS IRINOTECAN | ADVANCED PANCREATIC-CANCER | CLINICAL PHARMACOKINETICS | FLUOROURACIL | COMBINATION | ONCOLOGY | COLORECTAL-CANCER | PHARMACOLOGY & PHARMACY | PHASE-I | Antimitotic agents | Metabolites | Antineoplastic agents | Pancreatic cancer | Analysis | Pharmacodynamics | Parameters | Computer simulation | Toxicity | Pharmacology | Optimization | Antitumor agents | Body size | Models | Mathematical models | Pharmacokinetics | Index Medicus
Irinotecan | Population pharmacokinetics | FOLFIRINOX | Nonlinear mixed effect modelling | Oxaliplatin | Medicine & Public Health | 5-Fluorouracil | Oncology | Cancer Research | Pharmacology/Toxicology | METABOLITES | LEUCOVORIN | OXALIPLATIN PLUS IRINOTECAN | ADVANCED PANCREATIC-CANCER | CLINICAL PHARMACOKINETICS | FLUOROURACIL | COMBINATION | ONCOLOGY | COLORECTAL-CANCER | PHARMACOLOGY & PHARMACY | PHASE-I | Antimitotic agents | Metabolites | Antineoplastic agents | Pancreatic cancer | Analysis | Pharmacodynamics | Parameters | Computer simulation | Toxicity | Pharmacology | Optimization | Antitumor agents | Body size | Models | Mathematical models | Pharmacokinetics | Index Medicus
Journal Article
15.
Full Text
Population pharmacokinetics of bevacizumab in cancer patients with external validation
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 8/2016, Volume 78, Issue 2, pp. 341 - 351
Bevacizumab is approved for various cancers. This analysis aimed to comprehensively evaluate bevacizumab pharmacokinetics and the influence of patient...
Population pharmacokinetics | Medicine & Public Health | External validation | Japan | Oncology | Cancer Research | Adult | Pharmacology/Toxicology | Asian | Bevacizumab | Cancer | CARBOPLATIN | LEUCOVORIN | PHASE-II | COMBINATION | FLUOROURACIL | CHEMOTHERAPY | PACLITAXEL | TRIAL | ONCOLOGY | GASTRIC-CANCER | PHARMACOLOGY & PHARMACY | CARCINOMA | Bevacizumab - administration & dosage | Drug Administration Schedule | Humans | Bevacizumab - pharmacokinetics | Half-Life | Male | Angiogenesis Inhibitors - pharmacokinetics | Clinical Trials, Phase IV as Topic | Neoplasms - drug therapy | Dose-Response Relationship, Drug | Tissue Distribution | Angiogenesis Inhibitors - administration & dosage | Asian Continental Ancestry Group | Clinical Trials, Phase III as Topic | Models, Biological | Sex Factors | Female | Neoplasms - pathology | Clinical Trials, Phase I as Topic | Clinical Trials, Phase II as Topic | Antimitotic agents | Cancer patients | Chemotherapy | Phosphatases | Analysis | Monoclonal antibodies | Albumin | Metastasis | Drug therapy | Antineoplastic agents | Original
Population pharmacokinetics | Medicine & Public Health | External validation | Japan | Oncology | Cancer Research | Adult | Pharmacology/Toxicology | Asian | Bevacizumab | Cancer | CARBOPLATIN | LEUCOVORIN | PHASE-II | COMBINATION | FLUOROURACIL | CHEMOTHERAPY | PACLITAXEL | TRIAL | ONCOLOGY | GASTRIC-CANCER | PHARMACOLOGY & PHARMACY | CARCINOMA | Bevacizumab - administration & dosage | Drug Administration Schedule | Humans | Bevacizumab - pharmacokinetics | Half-Life | Male | Angiogenesis Inhibitors - pharmacokinetics | Clinical Trials, Phase IV as Topic | Neoplasms - drug therapy | Dose-Response Relationship, Drug | Tissue Distribution | Angiogenesis Inhibitors - administration & dosage | Asian Continental Ancestry Group | Clinical Trials, Phase III as Topic | Models, Biological | Sex Factors | Female | Neoplasms - pathology | Clinical Trials, Phase I as Topic | Clinical Trials, Phase II as Topic | Antimitotic agents | Cancer patients | Chemotherapy | Phosphatases | Analysis | Monoclonal antibodies | Albumin | Metastasis | Drug therapy | Antineoplastic agents | Original
Journal Article